EBR:OXUR - Euronext Brussels - BE0974487192 - Common Stock - Currency: EUR
EBR:OXUR (5/6/2025, 3:40:32 PM)
0.074
-0.01 (-7.27%)
The current stock price of OXUR.BR is 0.074 EUR. In the past month the price decreased by -36.54%. In the past year, price increased by 73900%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 18.48 | 295.77B | ||
1ABBV.MI | ABBVIE INC | 18.36 | 294.00B | ||
AMG.DE | AMGEN INC | 13.11 | 129.04B | ||
1GILD.MI | GILEAD SCIENCES INC | 13.7 | 116.36B | ||
GIS.DE | GILEAD SCIENCES INC | 13.22 | 112.29B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1501.35 | 100.35B | ||
ARGX.BR | ARGENX SE | 370.33 | 34.60B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.11B | ||
IDP.DE | BIOGEN INC | 7.73 | 15.80B | ||
1MRNA.MI | MODERNA INC | N/A | 9.49B | ||
0QF.DE | MODERNA INC | N/A | 9.03B | ||
BIO.DE | BIOTEST AG | 64.92 | 1.67B |
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Leuven (Louvain), Vlaams-Brabant and currently employs 11 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
OXURION NV
Gaston Geenslaan 1
LEUVEN (LOUVAIN) VLAAMS-BRABANT BE
Employees: 11
Phone: 3216751310
The current stock price of OXUR.BR is 0.074 EUR. The price decreased by -7.27% in the last trading session.
The exchange symbol of OXURION NV is OXUR and it is listed on the Euronext Brussels exchange.
OXUR.BR stock is listed on the Euronext Brussels exchange.
OXURION NV (OXUR.BR) has a market capitalization of 342.62K EUR. This makes OXUR.BR a Nano Cap stock.
OXURION NV (OXUR.BR) currently has 11 employees.
OXURION NV (OXUR.BR) has a resistance level at 0.09. Check the full technical report for a detailed analysis of OXUR.BR support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OXUR.BR does not pay a dividend.
OXURION NV (OXUR.BR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.48).
ChartMill assigns a technical rating of 2 / 10 to OXUR.BR. When comparing the yearly performance of all stocks, OXUR.BR is one of the better performing stocks in the market, outperforming 99.98% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to OXUR.BR. OXUR.BR has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months OXUR.BR reported a non-GAAP Earnings per Share(EPS) of -1.48. The EPS increased by 99.36% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 3966.67% | ||
ROA | 2.09% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 42% to OXUR.BR. The Buy consensus is the average rating of analysts ratings from 9 analysts.